Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma

NCT04911998 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT04911998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04911998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma
Lead sponsor
Pierre Fabre Medicament
Phase
Observational
Overall status
Completed
Start date
February 2, 2021
Completion date
March 29, 2024
Enrollment
400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, melanoma (skin), metastatic melanoma